|
|
 Previous Article | Table of Contents | Next Article 
International Prognostic Index for aggressive non-Hodgkin's lymphoma is
valid for all malignancy grades
J Hermans, AD Krol, K van Groningen, PM Kluin, JC Kluin-Nelemans, MH Kramer, EM Noordijk, F Ong and PW Wijermans
Department of Medical Statistics, University of Leiden, The Netherlands.
An International Prognostic Index (IPI) for patients with aggressive
non-Hodgkin's lymphoma (NHL) has recently been published. The IPI is based
on pretreatment clinical characteristics and developed on clinical trial
patients, classified as intermediate grade according to the Working
Formulation (WF). We applied this IPI in a population-based registry of NHL
patients. This registry does not have the restrictions that usually hold
for patients in clinical trials, eg, with respect to age and performance
status. Moreover, it covers all the three WF classes (low, intermediate,
and high). The IPI turned out to be of prognostic value for response rate
and survival in our unselected cohort of 744 patients, as well. In each of
the three WF classes separately, the four IPI classes showed going from low
to high substantially decreasing response rates and survival percentages.
For our cohort of WF intermediate grade patients 5-year survival levels
were lower in all four IPI classes (59%, 34%, 14%, and 10%, respectively),
probably reflecting the selection of clinical trial patients in the
original study (73%, 51%, 43%, and 26%).
Volume 86,
Issue 4,
pp. 1460-1463,
08/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. Glas, M. J. Kersten, L. J. M. J. Delahaye, A. T. Witteveen, R. E. Kibbelaar, A. Velds, L. F. A. Wessels, P. Joosten, R. M. Kerkhoven, R. Bernards, et al.
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment
Blood,
January 1, 2005;
105(1):
301 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Katahira, T. Takayama, K. Miyanishi, T. Hayashi, T. Ikeda, Y. Takahashi, R. Takimoto, T. Matsunaga, J. Kato, and Y. Niitsu
Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV)
Clin. Cancer Res.,
December 1, 2004;
10(23):
7934 - 7940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Solal-Celigny, P. Roy, P. Colombat, J. White, J. O. Armitage, R. Arranz-Saez, W. Y. Au, M. Bellei, P. Brice, D. Caballero, et al.
Follicular Lymphoma International Prognostic Index
Blood,
September 1, 2004;
104(5):
1258 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-S. Chim, S.-Y. Ma, W.-Y. Au, C. Choy, A. K. W. Lie, R. Liang, C.-C. Yau, and Y.-L. Kwong
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index
Blood,
January 1, 2004;
103(1):
216 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Ann. Onc.,
June 1, 2002;
13(6):
928 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment
J. Clin. Oncol.,
September 17, 2000;
18(17):
3135 - 3143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu
A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma
Blood,
November 15, 1999;
94(10):
3334 - 3339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Decaudin, E. Lepage, N. Brousse, P. Brice, J.-L. Harousseau, K. Belhadj, H. Tilly, L. Michaux, S. Cheze, B. Coiffier, et al.
Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients--A Study of the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol.,
August 1, 1999;
17(8):
2499 - 2499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al.
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
J. Clin. Oncol.,
June 1, 1999;
17(6):
1851 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen
Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
May 1, 1999;
5(5):
1085 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. ten Berge, D. F. Dukers, J. J. Oudejans, K. Pulford, G. J. Ossenkoppele, D. de Jong, J. F.M.M. Misere, and C. J.L.M. Meijer
Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma
Blood,
April 15, 1999;
93(8):
2688 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Ristamaki, H. Joensuu, K. Lappalainen, L. Teerenhovi, and S. Jalkanen
Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma
Blood,
November 15, 1997;
90(10):
4039 - 4045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu
A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma
Blood,
October 15, 1997;
90(8):
3167 - 3172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsunoda, S. Takagi, O. Tanaka, and Y. Miura
Clinical and Prognostic Significance of Femoral Marrow Magnetic Resonance Imaging in Patients With Malignant Lymphoma
Blood,
January 1, 1997;
89(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
